BillionToOne reported a major Q1 revenue increase driven by prenatal testing volume growth and set expectations for its Unity Confirm follow-on assay to further differentiate the portfolio. The company said Unity Confirm, a circulating fetal cell-based, non-invasive confirmation test for high-risk screening results, is expected to drive uptake of its Unity Aneuploidy screening platform. BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year over year, while Q1 prenatal testing revenue reached $96.5 million. The company said it accessioned 189,000 tests in Q1 and delivered 188,000 tests in the recently completed quarter. The company also disclosed that Unity Confirm launch dynamics should yield relatively low direct volumes—less than 1% of screening patients are expected to need follow-up—but it expects referral and provider workflow leverage to raise aneuploidy test utilization. Separately, the company is enrolling patients for a prospective trial comparing Unity Confirm against invasive confirmation methods such as CVS, with initial concordance data cited as 100% in earlier comparisons.